| Literature DB >> 33841915 |
Fabio D'Angelo1, Luca Monestier2, Luigi Zagra3.
Abstract
Treatment of bacterial septic arthritis in the native adult hip joint can be challenging. Prompt diagnosis and treatment decisions can reduce the associated morbidity and mortality.For this systematic review of the literature, we asked: (1) What are the treatment options? (2) What are the success rates and the outcomes after treatment? (3) Which antibiotic and duration of therapy are optimal?We searched the electronic databases PubMed, Scopus, and Embase using the search terms "hip" or "native hip" and "septic arthritis" or "coxitis". Studies were included if they reported on: (1) bacterial infection of the hip, (2) treatment, (3) success rate/outcomes, (4) follow-up. The final review included 19 studies. The quality of study reporting was evaluated with the Methodological Index for Non-randomized Studies (MINORS) questionnaire.Three treatment options are: arthroscopy, single open surgery, and two-stage total hip arthroplasty (THA). A high success rate in infection eradication was reported for all three. Intravenous antibiotic therapy should be promptly initiated to eradicate septic arthritis and minimize potential sequelae and complications.Arthroscopy, single open or two-stage THA were reported to be effective in treating bacterial septic arthritis of the native hip. The key to optimal outcome is early diagnosis and timely treatment. Cite this article: EFORT Open Rev 2021;6:164-172. DOI: 10.1302/2058-5241.6.200082.Entities:
Keywords: hip arthritis; septic arthritis; treatment
Year: 2021 PMID: 33841915 PMCID: PMC8025707 DOI: 10.1302/2058-5241.6.200082
Source DB: PubMed Journal: EFORT Open Rev ISSN: 2058-5241
Search terms for septic arthritis in the hip joint
| Search terms | PubMed | Embase | Scopus |
|---|---|---|---|
| “Hip/” OR “Hip native/” AND “septic arthritis/” OR “coxitis/” |
Fig. 1Study flowchart.
Note. THA, total hip arthroplasty; AVNF, AVascular Necrosis of Femoral head
Authors, journal, publication year, type of study, and MINORS score
| First author | Journal | Year of publication | Study design | Control group | MINORS score |
|---|---|---|---|---|---|
| Khazi ZM[ | 2020 | Retrospective case control | Arthrotomy | 15/24 | |
| Kao FC[ | 2019 | Retrospective case serie | NO | 13/16 | |
| Kim CH[ | 2018 | Retrospective case serie | NO | 11/16 | |
| Ohtsuru T[ | 2016 | Retrospective case control | Arthroscopy/ | 15/24 | |
| Anagnostakos K[ | 2016 | Retrospective case serie | NO | 7/16 | |
| Lee YK[ | 2014 | Retrospective case serie | NO | 13/16 | |
| Fleck EE[ | 2011 | Retrospective case serie | NO | 10/16 | |
| Kelm J[ | 2009 | Retrospective case serie | NO | 12/16 | |
| Nusem I[ | 2006 | Retrospective case serie | NO | 8/16 | |
| Yamamoto Y[ | 2001 | Retrospective case serie | NO | 8/16 | |
| de Sa D[ | 2015 | Systematic review | NO | ||
| Chen CE[ | 2008 | Retrospective case serie | NO | 13/16 | |
| Shen H[ | 2013 | Retrospective case serie | NO | 12/16 | |
| Cho YJ[ | 2018 | Retrospective case serie | NO | 10/16 | |
| Huang TW[ | 2010 | Retrospective case serie | NO | 10/16 | |
| Schröder JH[ | 2016 | Retrospective case serie | NO | 13/16 | |
| Romanò CL[ | 2011 | Prospective cohort | NO | 12/16 | |
| Kelm J[ | 2009 | Retrospective case serie | NO | 10/16 | |
| Papanna MC[ | 2018 | Retrospective case control | THA without spacer | 21/24 |
Note. MINORS, Methodological Index for Non-randomized Studies; THA, total hip arthroplasty.
Clinical data
| First author | No. patients | Age (yrs) | Sex | Follow-up (mths) | Pathogen | Treatment | Antibiotic | Antibiotic duration |
|---|---|---|---|---|---|---|---|---|
| Khazi ZM[ | 421 | n.a. | M 222, F 199 | Not reported | MSSA | 387 arthrotomy, 34 arthroscopy | Not reported | Not reported |
| Kao FC[ | 51 | 58.7 | M 32, | 48.8 | MSSA 3.9%, other 13.8%, multiple organisms 3.9%, not identified 78.4% | Debridement only 12, hip disarticulation 1, resection arthroplasty 38, cement spacer 28, THA 14 | Empiric antibiotic therapy, depending on sensitivity | 85 dys |
| Kim CH[ | 7 | 50.9 | M 4, | 16.0 | MSSA 42.9%, | Arthroscopy | Empiric antibiotic therapy, depending on sensitivity | 4–6 wks |
| Ohtsuru T[ | 15 | 55.9 | M 9, | Not reported | MRSA 33.3%, MSSA 20.0%, other 40.0%, not identified 6.66% | Group A: arthroscopy, debridement, resection arthroplasty, spacer 10; musculocutaneous flap transposition 5 | Vancomycin | 4 wks intravenous + 2 wks oral |
| Anagnostakos K[ | 22 | 59.7 | M 11, | 44.8 | MSSA 72.7%, not identified 27.3% | Two stage: moduled spacer + THA | Empiric antibiotic therapy, depending on sensitivity | 6 wks |
| Lee Y[ | 9 | 45.0 | M 4, | 18.0 | MSSA 44.4%, not identified 55.6% | Arthroscopy | Empiric antibiotic therapy, depending on sensitivity | 4–6 wks |
| Fleck EE[ | 14 | 60.8 | M 7, | 50.0 | MSSA 35.7%, MRSA 21.4%, other 21.4%, not identified 21.4% | Prostalac spacer | Empiric antibiotic therapy, depending on sensitivity | 6 wks |
| Kelm J[ | 28 | 71.0 | M 11, | 36.0 | MSSA 10.7%, MRSA 10.7%, | VAC therapy | Empiric antibiotic therapy, depending on sensitivity | 2 wks intravenous + 2 wks oral |
| Nusem I[ | 6 | 24.0 | M 3, | 22.0 | MSSA 66.6%, other 16.7%, not identified 16.7% | Arthroscopy | Empiric antibiotic therapy, depending on sensitivity | 3 wks intravenous + 3 wks oral |
| Yamamoto Y[ | 4 | 59.0 | M 1, | 32.0 | MSSA 50.0%, other 50.0% | Arthroscopy | Cefazolin + Cefdinir | 1 wk Cefazolin oral + 1 wk Cefdinir 300 mg oral |
| de Sa D[ | ||||||||
| Chen CE[ | 28 | 53.0 | M 22, | 77.0 | MSSA 21.4%, MRSA 28.6%, other 50.0% | Resection arthroplasty + THA 14; resection arthroplasty + gentamycin spacer + THA 14 | Empiric antibiotic therapy, depending on sensitivity | 4 wks |
| Shen H[ | 5 | 39.6 | Not reported | Spacer + THA | Not reported | 6 wks | ||
| Cho YJ[ | 9 (10 hips) | 44.6 | M 5, | 44.9 | MSSA 40.0%, other 20.0%, not identified 40.0% | Spacer + THA | Vancomycin 1 g + Cefazedone 1 g | Twice for 3 wks intravenous + 3 wks oral |
| Huang TW[ | 14 (15 hips) | 54.3 | M 9, | 42.5 | MSSA 28.6%, MRSA 28.6%, other 21.4%, not identified 21.4% | Spacer | Empiric antibiotic therapy, depending on sensitivity | 1 wk intravenous |
| Schröder JH[ | 7 | 44.0 | M 4, | 27.0 | MSSA 28.2%, other 43.8%, not identified 28.2% | Arthroscopy | Empiric antibiotic therapy, depending on sensitivity | 4 wks intravenous |
| Romanò CL[ | 19 (20 hips) | 55.7 | M 9, | 56.6 | MSSA 35.0%, MRSA 20.0%, other 25.0%, not identified 20.0% | Spacer G | Empiric antibiotic therapy, depending on sensitivity | 4–6 wks |
| Kelm J[ | 10 | 66.0 | M 5, | 57.6 | MSSA 13.9%, 1 MRSA, 1 streptococcus, 3 not identified | Spacer + THA | Empiric antibiotic therapy, depending on sensitivity | 6 wks |
| Papanna MC[ | 36 | 58.0 | M 21, | 70.0 | MSSA 33.3%, MRSA 2.78%, other 2.78%, not identified 61.1% | Group A: resection arthroplasty, spacer + THA; Group B: THA | Empiric antibiotic therapy, depending on sensitivity | 3 dys to 4 mths, oral or intravenous |
Note. n.a., not available; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; THA, total hip arthroplasty; VAC, vacuum-assisted closure.
Arthroscopic treatment
| First author | No. patients | Follow-up (mths) | Antibiotic duration | Success rate | Complications |
|---|---|---|---|---|---|
| Khazi ZM[ | 421 | Not reported | Not reported | 100% | Total adverse events arthrotomy 75.71%, arthroscopy 52.94%; |
| Kim CH[ | 7 | 16 | 4–6 wks | 100% | Hip osteoarthritis 14.2%, |
| Lee YK[ | 9 | 18 | 4–6 wks | 88.8% after first arthroscopy, 100% after second arthroscopy | None |
| Nusem I[ | 6 | 22 | 3 wks intravenous + 3 wks oral | 100% | Not reported |
| Yamamoto Y[ | 4 | 32 | 1 wk Cefazolin oral + 1 wk Cefdinir 300 mg oral | 100% | Cartilage damage and detachment 100.0% |
| Schröder JH[ | 7 | 27 | 4 wks intravenous | 100% |
Two-stage treatment
| First author | No. of patients | Follow-up (mths) | Treatment | Antibiotic duration | Success rate | Complications |
|---|---|---|---|---|---|---|
| Kao FC[ | 51 | 48.8 | Debridement only 12, | 85 dys | 73.4% resection arthroplasty, 73% after spacer, 92.9% revision THA | Death 13.7%, recurrent infection 9.8% |
| Anagnostakos K[ | 22 | 44.8 | Moduled spacer + THA | 6 wks | 87% after one spacer, 100% after two spacers | After spacer 23% |
| Fleck EE[ | 14 | 50.0 | Prostalac spacer + THA | 6 wks | 92.8% after one spacer, 100% after two spacers | None |
| Chen CE[ | 28 | 77.0 | Resection arthroplasty + THA 14; resection arthroplasty + gentamycin spacer + THA 14 | 4 wks | 79% excellent, | Reinfection 10.7%, periprosthetic fracture 10.7%, aseptic loosening 7.1%, dislocation 7.1%, stem broken 3.5%, cerebellar haemorrhage 3.5% |
| Shen H[ | 5 | 39.6 | Spacer + THA | 6 wks | 100% | None |
| Cho YJ[ | 9 (10 hips) | 44.9 | Spacer + THA | Twice for 3 wks intravenous + 3 wks oral | 100% | None |
| Huang TW[ | 14 (15 hips) | 42.5 | Spacer + THA | 1 wk intravenous | 93% at first attempt, 100% at second attempt | 2 intraoperative fractures |
| Romanò CL[ | 19 (20 hips) | 56.6 | Spacer G + THA | 4–6 wks | 95% | 1 septic failure of revision stem |
| Kelm J[ | 10 | 57.6 | Spacer + THA | 6 wks | 80% | 1 spacer dislocation |
| Papanna MC[ | 36 | 70.0 | Group A resection arthroplasty, spacer + THA; group B THA | 3 days to 4 mths, oral or intravenous | 100% | Group A: heterotopic ossification 2 (12%), dislocation 1 (6%); Group B: heterotophic ossification 3 (17%), periprosthetic infection 1 (6%) |
Note. THA = total hip arthroplasty.
Open surgery
| First author | No. of patients | Follow-up | Treatment | Antibiotic duration | Success rate | Complications |
|---|---|---|---|---|---|---|
| Ohtsuru T[ | 15 | Not reported | Group A: arthroscopy, debridement, resection arthroplasty, spacer 10; musculocutaneous flap transposition 5 | 4 wks intravenous + 2 wks oral | 100% | Intramuscular abscess 6.66% |
| Kelm J[ | 28 | 36 mths | VAC therapy | 2 wks intravenous + 2 wks oral | 100% | Postoperative haemorrhage 3.6%, reinfection 7.2% |
Note. VAC, vacuum-assisted closure.